Edge Therapeutics (EDGE) versus The Competition Critical Comparison
Edge Therapeutics (NASDAQ: EDGE) is one of 286 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its rivals? We will compare Edge Therapeutics to similar businesses based on the strength of its analyst recommendations, valuation, risk, earnings, institutional ownership, dividends and profitability.
Institutional and Insider Ownership
50.3% of Edge Therapeutics shares are owned by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 36.2% of Edge Therapeutics shares are owned by insiders. Comparatively, 16.6% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Edge Therapeutics has a beta of 2.52, meaning that its stock price is 152% more volatile than the S&P 500. Comparatively, Edge Therapeutics’ rivals have a beta of 6.08, meaning that their average stock price is 508% more volatile than the S&P 500.
This table compares Edge Therapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Edge Therapeutics Competitors||-5,311.45%||-218.34%||-39.53%|
This is a breakdown of recent ratings for Edge Therapeutics and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Edge Therapeutics Competitors||863||3212||11657||232||2.71|
Edge Therapeutics presently has a consensus price target of $25.50, suggesting a potential upside of 178.99%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 45.41%. Given Edge Therapeutics’ higher probable upside, analysts clearly believe Edge Therapeutics is more favorable than its rivals.
Earnings and Valuation
This table compares Edge Therapeutics and its rivals revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Edge Therapeutics||N/A||-$38.82 million||-5.86|
|Edge Therapeutics Competitors||$284.28 million||$33.78 million||82.68|
Edge Therapeutics’ rivals have higher revenue and earnings than Edge Therapeutics. Edge Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Edge Therapeutics rivals beat Edge Therapeutics on 7 of the 12 factors compared.
Edge Therapeutics Company Profile
Edge Therapeutics, Inc. is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company’s initial product candidates target rare, acute, life-threatening neurological and other conditions. The Company’s product candidates utilize its programmable, biodegradable polymer-based development platform (the Precisa Platform), a delivery mechanism that seeks to enable targeted and sustained drug exposure and avoid the dose-limiting side effects associated with the current standards of care. The Company’s product candidates include EG-1962 and EG-1964. EG-1962 is a polymer-based microsphere containing nimodipine suspended in a diluent of sodium hyaluronate was developed using its Precisa development platform to improve patient outcomes following aneurysmal subarachnoid hemorrhage (aSAH).
Receive News & Ratings for Edge Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.